Skip Nav Destination
Issues
1 October 2020
-
Cover Image
Cover Image
![issue cover]()
The cover shows a multiplex immunofluorescence (MIF) image of a nonresponder HNSCC patient with minimal CD8+ T-cell infiltrates in a baseline tumor biopsy. CD8+ T cell infiltrates at baseline correlated with neoadjuvant anti–PD1 pathologic response in surgically resectable, advanced HNSCC. For details, see article by Uppaluri et al. on page 5140 of this issue.Close Modal - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
Special Report
CCR Translations
CCR Drug Updates
FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis
Shaily Arora; Sanjeeve Balasubramaniam; Wei Zhang; Lijun Zhang; Rajeshwari Sridhara; Dianne Spillman; Jaigi P. Mathai; Bradley Scott; Sarah J. Golding; Michael Coory; Richard Pazdur; Julia A. Beaver
Reviews
Clinical Trial Brief Report
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Matteo S. Carlino; Alexander M. Menzies; Victoria Atkinson; Jonathan S. Cebon; Michael B. Jameson; Bernard M. Fitzharris; Catriona M. McNeil; Andrew G. Hill; Antoni Ribas; Michael B. Atkins; John A. Thompson; Wen-Jen Hwu; F. Stephen Hodi; Alexander D. Guminski; Richard Kefford; Haiyan Wu; Nageatte Ibrahim; Blanca Homet Moreno; Georgina V. Long
Clinical Trials: Targeted Therapy
A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer
Michael J. Pishvaian; Hongkun Wang; Aiwu Ruth He; Jimmy J. Hwang; Brandon G. Smaglo; Sunnie S. Kim; Benjamin A. Weinberg; Louis M. Weiner; John L. Marshall; Jonathan R. Brody
Author Choice
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors
Ryan J. Sullivan; Jeffrey Weber; Sapna Patel; Reinhard Dummer; Matteo S. Carlino; Daniel S.W. Tan; Celeste Lebbé; Salvatore Siena; Elena Elez; Lance Wollenberg; Michael D. Pickard; Victor Sandor; Paolo A. Ascierto
Clinical Trials: Immunotherapy
Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275
Matthew D. Galsky; Abdel Saci; Peter M. Szabo; G. Celine Han; Gary Grossfeld; Sandra Collette; Arlene Siefker-Radtke; Andrea Necchi; Padmanee Sharma
A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer
Annie A. Wu; Katherine M. Bever; Won Jin Ho; Elana J. Fertig; Nan Niu; Lei Zheng; Rose M. Parkinson; Jennifer N. Durham; Beth Onners; Anna K. Ferguson; Cara Wilt; Andrew H. Ko; Andrea Wang-Gillam; Daniel A. Laheru; Robert A. Anders; Elizabeth D. Thompson; Elizabeth A. Sugar; Elizabeth M. Jaffee; Dung T. Le
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Ravindra Uppaluri; Katie M. Campbell; Ann Marie Egloff; Paul Zolkind; Zachary L. Skidmore; Brian Nussenbaum; Randal C. Paniello; Jason T. Rich; Ryan Jackson; Patrik Pipkorn; Loren S. Michel; Jessica Ley; Peter Oppelt; Gavin P. Dunn; Erica K. Barnell; Nicholas C. Spies; Tianxiang Lin; Tiantian Li; David T. Mulder; Youstina Hanna; Iulia Cirlan; Trevor J. Pugh; Tenny Mudianto; Rachel Riley; Liye Zhou; Vickie Y. Jo; Matthew D. Stachler; Glenn J. Hanna; Jason Kass; Robert Haddad; Jonathan D. Schoenfeld; Evisa Gjini; Ana Lako; Wade Thorstad; Hiram A. Gay; Mackenzie Daly; Scott J. Rodig; Ian S. Hagemann; Dorina Kallogjeri; Jay F. Piccirillo; Rebecca D. Chernock; Malachi Griffith; Obi L. Griffith; Douglas R. Adkins
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study
Kevin J. Harrington; Anthony Kong; Nicolas Mach; Jason A. Chesney; Beatriz Castelo Fernandez; Danny Rischin; Ezra E.W. Cohen; Hoi-Shen Radcliffe; Burak Gumuscu; Jonathan Cheng; Wendy Snyder; Lillian L. Siu
Precision Medicine and Imaging
Author Choice
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Nicholas C. Turner; Claire Swift; Lucy Kilburn; Charlotte Fribbens; Matthew Beaney; Isaac Garcia-Murillas; Aman U. Budzar; John F.R. Robertson; William Gradishar; Martine Piccart; Gaia Schiavon; Judith M. Bliss; Mitch Dowsett; Stephen R.D. Johnston; Stephen K. Chia
First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
Mark P.S. Dunphy; Christina Pressl; Nagavarakishore Pillarsetty; Milan Grkovski; Shanu Modi; Komal Jhaveri; Larry Norton; Bradley J. Beattie; Pat B. Zanzonico; Danuta Zatorska; Tony Taldone; Stefan O. Ochiana; Mohammad M. Uddin; Eva M. Burnazi; Serge K. Lyashchenko; Clifford A. Hudis; Jacqueline Bromberg; Heiko M. Schöder; Josef J. Fox; Hanwen Zhang; Gabriela Chiosis; Jason S. Lewis; Steven M. Larson
Author Choice
A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors
Mirte Muller; Karlijn Hummelink; Daan P. Hurkmans; Anna-Larissa N. Niemeijer; Kim Monkhorst; Joanna Roder; Carlos Oliveira; Heinrich Roder; Joachim G. Aerts; Egbert F. Smit
Author Choice
A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy
Carine El Sissy; Amos Kirilovsky; Marc Van den Eynde; Ana-Maria Muşină; Maria-Gabriela Anitei; Alfredo Romero; Florence Marliot; Audelaure Junca; Jérôme Doyen; Bernhard Mlecnik; Nacilla Haicheur; Tessa Fredriksen; Christine Lagorce; Anne Jouret-Mourin; Daniel Leonard; Frédéric Bibeau; Soledad Iseas; Enrique L. Roca; Ana M. Cabanne; Carlos A. Vaccaro; Juan P. Santino; Eduardo Huertas; David Tougeron; Carlos Carvalho; Nuno Figueiredo; Rodrigo O. Perez; Angelita Habr-Gama; Viorel Scripcariu; Jean-Pierre Gerard; Jérôme Galon; Guy Zeitoun; Franck Pagès
Translational Cancer Mechanisms and Therapy
Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma
Jean-Baptiste Bachet; Hélène Blons; Pascal Hammel; Iman El Hariry; Fabienne Portales; Laurent Mineur; Jean-Philippe Metges; Claire Mulot; Camille Bourreau; Jason Cain; Jérôme Cros; Pierre Laurent-Puig
Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Erik Ladomersky; Lijie Zhai; Kristen L. Lauing; April Bell; Jiahui Xu; Masha Kocherginsky; Bin Zhang; Jennifer D. Wu; Joseph R. Podojil; Leonidas C. Platanias; Aaron Y. Mochizuki; Robert M. Prins; Priya Kumthekar; Jeffrey J. Raizer; Karan Dixit; Rimas V. Lukas; Craig Horbinski; Min Wei; Changyou Zhou; Graham Pawelec; Judith Campisi; Ursula Grohmann; George C. Prendergast; David H. Munn; Derek A. Wainwright
Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts
Ranjit K. Mehta; Sanjima Pal; Koushik Kondapi; Merna Sitto; Cuyler Dewar; Theresa Devasia; Matthew J. Schipper; Dafydd G. Thomas; Venkatesha Basrur; Manjunath P. Pai; Yoshihiro Morishima; Yoichi Osawa; William B. Pratt; Theodore S. Lawrence; Mukesh K. Nyati
Advertisement
